

Invitation to presentation of Bactiguard's interim report for the first quarter 2026

Bactiguard Holding AB (publ) publishes its interim report for the first quarter on Thursday 23 April 2026 at 07:00 CET.

In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com.

To participate in the audiocast, please use this link: ir.bactiguard.com/report/q1-2026/

To participate only by conference call, please register via the link above.

Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

For further information, please contact:

Patrick Bach, CFO +46 761 295 911

About Bactiguard

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas where infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices. The company also has a portfolio of wound management products. Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard is headquartered in Stockholm and is listed on Nasdaq Stockholm and is included in the Small-Cap segment.

Read more about Bactiguard: www.bactiguard.com

Follow Bactiguard on [LinkedIn](#)